Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York
Mandate

Vinge has advised Aprea Therapeutics in connection with its listing on Nasdaq, New York

October 17, 2019 Capital Markets and Public M&A

Vinge has advised Aprea Therapeutics, Inc. and its subsidiary Aprea Therapeutics AB in connection with its listing on Nasdaq, New York.

The initial public offering price was set to $15 and the biopharmaceutical company sold 6.5 million shares in the IPO to raise $97.75 million. Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing cancer therapeutics.

 
Vinge’s team has primarily consisted of Kristina Ekberg, Charlotte Levin, Maria Schultzberg, Anna Thoms and Stina Bengtsson.

Related

Vinge has advised Terranor Group AB in connection with its listing on Nasdaq First North Growth Market

 Vinge has advised Terranor Group AB (publ) (“Terranor”) connection with its listing on Nasdaq First North Growth Market. The first day of trading in Terranor's shares is today 30 June 2025.
June 30, 2025

Vinge advises Keyto Group in connection with the acquisition of GreenThumb

KEYTO Group expands into the UK market as GreenThumb joins the group. This partnership marks KEYTO’s first entry in the UK and reinforces its ambition to build the leading, tech-enabled one-stop destination for home-related services internationally.
June 30, 2025

Vinge advises Odevo in the acquisition of Portik Group

 Vinge has advised Odevo, the internationally leading company within residential property management, in connection with the acquisition of Portik Group. Through the acquisition, Odevo continues its international expansion by establishing itself in Spain, Italy, Portugal and Mexico.
June 27, 2025